Management patterns and costs of acute ischemic stroke - An international study

被引:113
作者
Caro, JJ
Huybrechts, KF
Duchesne, I
机构
[1] Caro Res, Concord, MA 01742 USA
[2] McGill Univ, Royal Victoria Hosp, Div Gen Internal Med, Montreal, PQ H3A 1A1, Canada
[3] Janssen Res Fdn, B-2340 Beerse, Belgium
关键词
clinical trials; costs and cost analysis; stroke management;
D O I
10.1161/01.STR.31.3.582
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-With the ever-increasing pressure on healthcare budgets, we witness a growing demand for evidence of the economic implications of care across many therapeutic areas. Stroke is no exception. Methods-Detailed information on healthcare use was collected in conjunction with two 12-week international trials designed primarily to assess the safety and efficacy of a new potential neuroprotective agent. The information was gathered prospectively by means of a customized resource use instrument that included both acute and long-term inpatient management as well as community care. In this report, the results pertaining to the 1341 acute ischemic stroke patients are described. Results-More than 70% of the mean cost ($13 668) was explained by the initial hospitalization, which averaged 24 days. The total cost and its components varied according to patient age, the presence of comorbidities, and several indicators of disease severity. Pronounced country differences could be observed in the management of this fairly homogeneous patient group. Conclusions-This study provides a comprehensive picture of the healthcare services used for the treatment and rehabilitation of stroke victims, presented with respect to various patient and disease characteristics. It is expected that researchers evaluating the cost-efficiency of specific stroke treatments will benefit from the detailed information presented in this report.
引用
收藏
页码:582 / 590
页数:9
相关论文
共 25 条
[1]   CLASSIFICATION OF SUBTYPE OF ACUTE ISCHEMIC STROKE - DEFINITIONS FOR USE IN A MULTICENTER CLINICAL-TRIAL [J].
ADAMS, HP ;
BENDIXEN, BH ;
KAPPELLE, LJ ;
BILLER, J ;
LOVE, BB ;
GORDON, DL ;
MARSH, EE ;
KASE, CS ;
WOLF, PA ;
BABIKIAN, VL ;
LICATAGEHR, EE ;
ALLEN, N ;
BRASS, LM ;
FAYAD, PB ;
PAVALKIS, FJ ;
WEINBERGER, JM ;
TUHRIM, S ;
RUDOLPH, SH ;
HOROWITZ, DR ;
BITTON, A ;
MOHR, JP ;
SACCO, RL ;
CLAVIJO, M ;
ROSENBAUM, DM ;
SPARR, SA ;
KATZ, P ;
KLONOWSKI, E ;
CULEBRAS, A ;
CAREY, G ;
MARTIR, NI ;
FICARRA, C ;
HOGAN, EL ;
CARTER, T ;
GURECKI, P ;
MUNTZ, BK ;
RAMIREZLASSEPAS, M ;
TULLOCH, JW ;
QUINONES, MR ;
MENDEZ, M ;
ZHANG, SM ;
ALA, T ;
JOHNSTON, KC ;
ANDERSON, DC ;
TARREL, RM ;
NANCE, MA ;
BUDLIE, SR ;
DIERICH, M ;
HELGASON, CM ;
HIER, DB ;
SHAPIRO, RA .
STROKE, 1993, 24 (01) :35-41
[2]  
AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113
[3]   STROKE REHABILITATION OUTCOME - A POTENTIAL USE OF PREDICTIVE VARIABLES TO ESTABLISH LEVELS OF CARE [J].
ALEXANDER, MP .
STROKE, 1994, 25 (01) :128-134
[4]  
[Anonymous], UNIT COSTS HLTH SOCI
[5]  
Arboix A, 1997, ACTA NEUROL SCAND, V96, P407
[6]  
Asplund K, 1997, BMJ-BRIT MED J, V314, P1151
[7]   Hospital services for stroke care - A European perspective [J].
Beech, R ;
Ratcliffe, M ;
Tilling, K ;
Wolfe, C .
STROKE, 1996, 27 (11) :1958-1964
[8]   STROKE SUBTYPE IS AN AGE-INDEPENDENT PREDICTOR OF 1ST-YEAR SURVIVAL [J].
BRAININ, M ;
SEISER, A ;
CZVITKOVITS, B ;
PAULY, E .
NEUROEPIDEMIOLOGY, 1992, 11 (4-6) :190-195
[9]   International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS [J].
Caro, J ;
Klittich, W ;
McGuire, A ;
Ford, I ;
Pettitt, D ;
Norrie, J ;
Shepherd, J .
EUROPEAN HEART JOURNAL, 1999, 20 (04) :263-268
[10]   Stroke treatment economic model (STEM) - Predicting long-term costs from functional status [J].
Caro, JJ ;
Huybrechts, KF .
STROKE, 1999, 30 (12) :2574-2579